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Abstract  
INTRODUCTION: Thyroid malignomas are a heterogeneous group of neoplasm consisting of most 
frequent differentiated encountered carcinomas, papillary and follicular thyroid carcinoma, then 
medullary thyroid carcinoma originating from neuroendocrine calcitonin-producing C-cells and rare 
forms of thyroid lymphomas arising from intrathyroidal lymphatic tissue, thyroid sarcomas and 
poorly differentiated anaplastic thyroid carcinoma. There are increasing numbers of epidemiological 
studies and publications that have suggested increased incidence rate of thyroid carcinomas. We 
have read, analysed and compare available reviews and original articles investigating different 
etiological factors in the development of thyroid carcinomas through Google Scholar and PubMed 
Database. 
DISCUSSION: Aetiology involved in the development of thyroid carcinomas is multifactorial and 
includes external influences, as well as constitutional predispositions and genetic etiological factors. 
The actual effect of environmental and constitutional factors is on promoting genetic and epigenetic 
alterations which result in cell proliferation and oncogenesis. Until now are identified numerous 
genetic alterations, assumed to have an important role in oncogenesis, with MAPK and PI3K-AKT 
as crucial signalling networks regulating growth, proliferation, differentiation and cell 
survival/apoptosis.  
CONCLUSION: This new molecular insight could have a crucial impact on diagnosis and also on 
improving and selecting an appropriate treatment to the patients with thyroid malignancies. 
 
 
 
 
Introduction 
 
Classification of thyroid malignomas 
Thyroid malignomas (TM) are a 
heterogeneous group of neoplasm, which according to 
histopathological features are grouped in neoplasm 
originating from epithelial follicular cells, the 
differentiated thyroid carcinomas with the most 
frequent variants, papillary and follicular carcinoma 
and medullary thyroid carcinoma originating from 
neuroendocrine calcitonin-producing C-cells. Very 
rare forms of primary thyroid neoplasm are thyroid 
lymphomas arising from intrathyroidal lymphatic tissue 
and thyroid sarcomas, developing probably from cells 
of the intrathyroidal connective tissue [1, 2]. In 
separate category is poorly differentiated anaplastic 
thyroid carcinoma, which according to prognosis is 
one of the most aggressive tumours, but is very rare 
with only 1 – 2 % of all TM [3].  
Papillary thyroid carcinoma (PTC) is the most 
common variant of TM, with the representation of 
around 80% according to the most studies, but this 
category of TM isn’t homogenous. There are several 
histopathological variants of PTC described which are: 
typical variant, follicular variant, microcarcinoma, tall 
cell, oncocytic, columnar cell, diffuse sclerosing, solid, 
clear cell, cribriform morular, macrofollicular, PTC with 
fasciitis – like stroma, relatively rare and newly 
described Warthin – like PTC, mixed papillary and 
medullary carcinoma and papillary with 
dedifferentiation in anaplastic carcinoma [4-7].  
Category of well-differentiated TM includes 
also follicular carcinoma (FC). According to 
appropriate chapter of WHO Classification of Tumours 
of Endocrine Organs, FC is defined as malignant 
epithelial tumours with follicular cell differentiation, 
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without the presence of specific diagnostic nuclear 
characteristics for PTC. Data from the study of 
Manuel Sobrinho-Simões et al. indicate declining 
incidence of this category TM from entirely not known 
reasons [8]. Frequent detection of follicular variant of 
PTC and worldwide conducted projects for correction 
of iodine deficiency are assumed main reasons for 
detected decline in the incidence rate of FC. 
According to the epidemiological data, FC is 
accounting for about 10% of all thyroid carcinomas, 
but the biggest diagnostic challenge is exact 
discrimination between follicular adenomas (FA) from 
minimally invasive follicular thyroid carcinomas and 
encapsulated follicular variant of PTC [8]. Among 
other variants of TM, FC includes also Oncocytic 
Hurthle cell variant [2, 9, 10]. 
 
Epidemiology  
Epidemiological data indicate that TM are the 
most frequent endocrinological neoplasm and 
according to the latest evaluations they participate 
with around 1 % in all malignomas [11-13]. An 
epidemiological study from US National Cancer 
Institute од Surveillance, Epidemiology and End 
Results (SEER) program for the period 1975 to 2012 
year registered 13.5 newly diagnosed cases of thyroid 
carcinomas per 100 000 people per year. The 
mortality rate from thyroid carcinomas was 0.5 deaths 
per 100 000 persons, per year and is estimated that 
approximately 1.1 % of the population will be 
diagnosed with TM at some point in life, extrapolated 
from statistical data for the American population for 
the period 2011 – 2012 [14]. According to the data 
published in guidelines of American Thyroid 
Association (ATA, 2015) incidence rate per year for 
well-differentiated thyroid carcinomas almost tripled 
from only 4.9/100 000 in 1975 to 14.3/100 000 in 
2009. Analysis showed that almost all increase is due 
to the rise in the incidence rate of PTC thus 39% of 
the cases detected in 2008/09 were < 1cm [15]. Carlo 
La Vecchia et al. using available data from WHO, 
published detailed epidemiological study regarding 
incidence, prevalence and mortality rate of TM in 
countries from Europe, North, Central and South 
America and Asia. Main conclusions from the study 
were that the highest increase in mortality rate was 
detected in countries of Central America and Asia and 
in countries of East and Central Europe and lowest 
mortality in countries of Western Europe and North 
America. Valuable acknowledgement from this study 
was that there is a continuous decrease in overall 
mortality from TM, although in the same time increase 
in incidence rate of thyroid carcinomas in all countries 
included in epidemiological analysis through all 
continents was detected. Investigations were in the 
direction of detecting potential exposure to 
geographical risk factors responsible for the change in 
incidence and mortality rate. Some of the regions with 
the high mortality rate included territories with iodine 
deficiency in the past, with also highest incidence of 
benign thyroid disorders, goitre and benign thyroid 
nodules/adenomas, which are considered as one of 
the most significant risk factors for the development of 
TM [16]. Conclusions from this and similar studies 
suggest that increased incidence of thyroid 
carcinomas may be also due to the improvement in 
diagnostic tools and early detection of small 
microcarcinomas less than 1 cm in diameter. 
According to others one of the dominant risk factors is 
increased exposition to radiation, mostly due to 
inappropriate use in diagnostic and therapeutic 
purposes [17, 18]. 
 
 
Discussion  
 
Environmental etiological factors 
  Etiological factors involved in the 
development of TM are multifactorial and include 
external influences and constitutional predispositions 
and genetic etiological factors [1]. Because of the 
heterogeneous character of this neoplasm, according 
to originating cells, histopathological features, genetic 
factors, differences in therapeutic protocols and 
prognosis, the focus of this review will be on the 
etiopathogenesis of well-differentiated thyroid 
carcinomas, originated from epithelial follicular cells. 
The most studied risk factor in the oncogenesis of TM 
is radiation exposition during childhood, confirmed in 
numerous publications that significantly increase the 
risk for development of thyroid carcinomas. 
Unfortunately first observations about the connection 
between radiation exposition of neck during childhood 
and increased risk for development of thyroid 
carcinomas are studies of children which in period 
from 1940 till 1950 underwent local irradiation 
treatment of the head and neck for infection and 
inflammation of tonsillar and nasopharyngeal region 
and also irradiation therapy of acne and thymus [19]. 
Long term follows up of this children, showed the 
frequent occurrence of nodules in the thyroid gland 
and an insignificant number of these children was 
diagnosed thyroid carcinoma [20, 21]. Later gathered 
data of population from Hiroshima and Nagasaki 
atomic bombing were in concordance with these first 
observations. Furukawa et al. published one of the 
most thorough analyses on this issue. His study is 
authentic and gives important contribution because of 
the fact that evaluation and follow-up of a large 
number of exposed subjects in period 1958 – 2005 
were conducted including 105,401 exposed persons. 
Using linear dose – response model, increased the 
relative risk of 1.28 (95% confidence interval 0.95-2.7) 
for thyroid carcinoma after radiation exposition of 1 Gy 
was calculated at the age of 60 years, after acute 
exposition in childhood at 10 years age. Results of 
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this study showed that increased relative risk for 
development of thyroid carcinoma in a population that 
was exposed to radiation in early childhood; persist 
even after a long latent period of 50 years, although 
this relative risk is very low [22, 23]. Facts for the 
deleterious effect of radiation exposition in the 
development of thyroid carcinoma in population from 
Hiroshima and Nagasaki later were confirmed after 
Chernobyl nuclear power plant accident. Increased 
incidence rate was detected even in the first 3 – 4 
years after the accident, especially in the youngest 
population in the age group up to the age of 4 years. 
Highest incidence increment of paediatric thyroid 
carcinomas was detected in the region of Chernobyl 
and in place Gomel in Belarus as a result of 
exposition to 
131
I radioisotope and the additional 
predisposing factor was iodine deficiency of the 
population [24]. Schonfeld et al. suggested that latent 
period between exposition and manifestation of the 
disease was at least 5 years, while in the study of 
Cardis et al. incidence increment after irradiation in 
Chernobyl was detected after only 3 years. The 
relative risk for development of TM was highest after a 
period of 20 years, and it reduces after this period. 
The evaluated relative risk exists at mean exposition 
dose of 10 cGy and above this exposition dose up to 
1500 cGy exists linear dependence between 
irradiation and risk for development of TM. Higher 
expositions above 1500 cGy are associated with a 
reduction in relative risk, probably because of the 
cytotoxic effect of this high exposition doses. Besides 
irradiation, important constitutional factor was the age 
of the children, it was detected that age above 15 
years is accompanied with reduced risk for 
development of TM after exposition to irradiation [19].  
Another environmental factor in the 
etiopathogenesis of TM is assumed to be iodine diet 
intake (nutritive iodine deficiency or sufficiency) [23]. It 
is well-known fact that low but also high intake of 
iodine may result in changes of TSH. Experimental 
animal studies showed that both conditions could be 
stimulating cancerogenic factors. Studies with 
prolonged nutritive iodine deficiency with 
simultaneous use of known cancerogenic agents such 
as chemical mutagens resulted in a significantly 
higher incidence of TM in experimental animal 
studies. According to this survey iodine deficiency has 
impact more like promoter, not like direct 
cancerogenic agent through inducing increase of 
TSH, and TSH stimulation stimulates 
autocrine/paracrine regulated thyroid EGF (Еpidermal 
growth factor) stimulated proliferation, lowering in the 
same time TGFβ1 (Transforming growth factor β1), 
which acts as a negative factor of thyroid cell 
proliferation, which results in increased angiogenesis 
and promoting tumor growth [25]. A number of studies 
showed a high incidence of follicular and anaplastic 
carcinomas in population from iodine deficiency 
regions. Studies with increased iodine ingestion and 
risk of TM are inconclusive. Rossing et al. in a study 
conducted among Asian women originating from 
Philippines and Japan but living in America, detected 
higher incidence in those born in Asia and later settled 
in America in comparison to those born in America. 
Authors concluded that this difference in incidence 
rate may be the result of environmental influences 
(perhaps due to nutritive differences), which act in the 
later stages of cancerogenesis and that those 
influences are reversible [26].  
 
Constitutional etiological factors 
Pre-existing benign thyroid disease is also 
one of the risk factors for the development of TM. 
According to several case-control studies and 
prospective studies, both benign thyroid 
nodular/multinodular disease and goitre, autoimmune 
disorders (Graves’s disease and Hashimoto disease) 
are described as conditions for increased risk for 
developing TM, although biases cannot be excluded 
[27].  
Because of significant difference in incidence 
rate of TM between females and males after puberty 
and in reproductive period, it was suggested possible 
oestrogen effects in the development of thyroid 
carcinomas. Cheng GG et al, in their in vitro study, 
demonstrated that oestrogen receptors are present on 
thyroid cancer cell lines [28].  
 Obesity is another risk factor detected through 
numerous case-control studies. The exact 
pathophysiological mechanism is not entirely known, 
but an increase of TSH and interplay of TSH and 
insulin – like growth factor 1 inactivation of MAPK and 
PI3K pathways in obese patients may be enrolled in 
pathogenesis [29]. 
High incidence of papillary carcinoma is 
registered in patients with familial adenomatous 
polyposis and Cowden’s disease (multiple hamartoma 
Sy). Thyroid carcinomas are mostly sporadic, but in 
5% are with familial appearance, with determined few 
loci in predisposing genes in this families [30].  
 
Genetic alterations 
Further elucidation of oncogenesis of thyroid 
carcinomas can be achieved with recent 
developments in molecular biology and identification 
of genetic abnormalities in patients with TM. Some 
identified genetic alterations in patients with thyroid 
carcinomas are changes in tyrosine kinase domain of 
RET gene in 15 – 33 %, RAS mutations detected in 
10% and B-RAF mutations in 40-60% of cases. 
Several molecular alterations were identified in last 
year’s, which included genetic and epigenetic 
alterations in signalling pathways, like MAPK 
(Mitogen-activated protein kinases are known also as 
ERK – extracellular signal-regulated kinases) pathway 
responsible for tumour initiation and PI3K-AKT 
signalling pathway for progression and 
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dedifferentiation of thyroid carcinomas. Molecular 
mechanisms involved in the pathogenesis of TM can 
be divided into genetic and epigenetic alterations. 
Genetic alterations can be also classified as nuclear 
genetic mutations, genetic rearrangements and loss of 
heterogeneity, while epigenetic changes can be DNA 
mutilation, histone modification and genetic silencing 
through microRNA. Nuclear genetic mutations include 
activation of MAPK pathway. Activation of this 
pathway in thyroid carcinomas is through RET/PTC 
rearrangement, RAS mutations and BRAF mutations. 
MAPK pathway is a network of three kinases which 
successfully activates one another through sequential 
phosphorylation in response to various stimulating 
factors, like growth factors, cytokines, 
neurotransmitters, cellular stress and cell adhesion. 
This complex activating network participates in the 
regulation of numerous cellular processes, among 
which is control of cell growth, differentiation, cellular 
adaptation to chemical and physical stress. In RAF-
RAS/MEK/ERK pathway signalling transduction starts 
with activation of small molecule GTPase RАS, 
through receptor tyrosine kinases, G – protein coupled 
receptors and/or integrins. These membrane proteins 
are a group of signalling complexes which activates 
RAS proteins through changes in RАS – GTP, active 
or RАS – GDP, inactive form. RAS mutations cause 
inactivation of GTP are resulting in permanent active 
RAS- GTP form. There are 3 isoforms of RAS: HRAS, 
КRAS and NRAS found in thyroid tumours. RAS 
mutations are usually found in follicular thyroid 
adenomas, suggesting that those mutations occur 
early in the development of premalignant lesions and 
additional genetic alteration can trigger malignant 
transformation to follicular adenomas. Presumably, 
KRAS and concomitant PTEN deletion can induce 
malignant transformation in the aggressive form of 
follicular thyroid carcinoma. Mutations and deletions of 
tumour suppressor PTEN gene are genetic alterations 
which activate PI3K-AKT pathway and are a genetic 
basis for follicular thyroid carcinoma in Cowden’s Sy 
[31]. While RAS mutations are characteristic for 
follicular thyroid neoplasms, RET/PTC proto-
oncogenes are almost exclusively found in PTC. 
Development of TM very similar to PTC in humans 
was detected in experimental models of mice with 
RET/PTC expression. There are variations in the 
prevalence of RET/PTC oncogenes in PTC, but the 
highest frequency was detected in tumours occurring 
in children after radiation exposition [32]. At least 10 
different RET/PTC oncogenes are described as a 
result of the fusion of tyrosine kinase domain on RET 
5' part of different genes. RET/PTC1 and RET/PTC3 
are most common types of all rearrangement with 
>90% participation [33]. Another relatively often 
detected genetic alteration, which is experimentally 
proven in around 45% of PTC is T1799A transverse 
point mutation of BRAF (mutation of the gene for B- a 
type of RAF kinase), manifesting with an expression 
of BRAF - V600E mutated protein, resulting in 
successive activation of serine/threonine kinase. One 
extensive multicentric study showed a strong 
association of BRAF - V600E mutated protein with the 
worst prognostic outcome and more aggressive form 
of PTC, usually associated with tall cell variant of PTC 
and lost of iodine avidity and, because of that, 
resistance on radioiodine treatment [34].  
Besides changes in MAPK pathway important 
for oncogenesis are changes in the PI3K-AKT 
signalling pathway, which stimulates cell proliferation. 
PTEN tumour suppressor gene (phosphate and tensin 
homolog), localised on the 10q23 chromosome is an 
inhibitor of this pathway, acting as a natural restrictor 
of cell proliferation, preventing the tumour growth [35]. 
Various changes, like mutations, deletion and 
silencing of this gene are described. TP53 is tumour 
suppressor gene localised to chromosome 17 and it is 
considered that dedifferentiation in the evolution of the 
tumours may be due to the mutations of this gene. 
Genetic rearrangement like translocation results in 
creating a new protein with oncogenic features. W 
Chien et al in their study Molecular biology of thyroid 
cancer, indicate the presence of chromosomal 
translocation t(2;3)(q13;p25), PAX8/PPARγ 
rearrangement, with a fusion of PAX8, thyroid-specific 
transcription factor to PPARγ, nuclear hormone 
receptor involved in differentiation of cells. This 
genetic rearrangement was found in 36% of FC 
(Follicular thyroid carcinoma), 11% of Follicular 
adenoma and 13 % of Follicular variant of PTC [36, 
37]. Understanding of molecular processes 
contributed to the thorough investigation of molecular 
pathogenesis in well-differentiated thyroid carcinomas.  
 
 
Figure 1: Molecular mechanisms in Thyroid carcinomas. (Asuragen 
Inc. White Paper: Molecular Pathogenesis of Thyroid Cancer) 
 
In conclusion we can resume that in the 
development of TM complex mechanisms of 
interaction between environmental factors, radiation 
exposition, especially in early childhood, nutritive 
factors with particular emphasis on iodine intake, 
chemical mutagen agents and on the other hand 
internal constitutional predispositions age, sex, 
obesity and previous thyroid disorders as multinodular 
goiter could have impact. The actual effect of these 
environmental and constitutional factors is to promote 
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genetic and epigenetic alterations which result in cell 
proliferation and oncogenesis. Till now numerous 
genetic alterations are identified that have an 
important role in oncogenesis, with MAPK and PI3K-
AKT being crucial signalling networks regulating 
growth, proliferation, differentiation and cell 
survival/apoptosis. Changes in a different segment of 
this pathways result in activation of oncogenesis in 
TM. Different disorders, such as inflammatory, 
immunological and degenerative processes, could 
initiate impairment of complex signalling networks and 
this new molecular insight could have a crucial impact 
on improving and selecting appropriate treatment for 
patients with TM [38].  
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